Literature DB >> 26965062

[Posterior Reversible Encephalopathy Syndrome Associated with Cancer Therapy].

Koichi Mitsuya1, Yoko Nakasu, Nakamasa Hayashi, Hirofumi Yasui, Takashi Ikeda, Shiho Kuji, Yusuke Onozawa, Masahiro Endo.   

Abstract

Posterior reversible encephalopathy syndrome(PRES)is a subacute neurological syndrome typically manifesting with headache, cortical blindness, and seizures. This syndrome is associated with risk factors such as malignant hypertension, eclampsia, and renal failure. Numerous case reports depict its occurrence in cancer patients. The direct causal mechanisms of PRES in cancer patients have not yet been identified. Cytotoxic chemotherapy may cause direct endothelial damage, which would impact the blood brain barrier. Angiogenesis inhibitors also cause elevation in blood pressure;this is significant, because PRES onset may be solely related to hypertension. An increased number of case reports involving new molecular targeted agent suggests that incidence of PRES as an oncological emergency may increase in the future.

Entities:  

Mesh:

Year:  2016        PMID: 26965062     DOI: 10.11477/mf.1436203259

Source DB:  PubMed          Journal:  No Shinkei Geka        ISSN: 0301-2603


  1 in total

1.  A case report of posterior reversible encephalopathy syndrome in a patient receiving gemcitabine and cisplatin.

Authors:  Hannah Cherniawsky; Neesha Merchant; Micheal Sawyer; Maria Ho
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.